Linear bisphosphonates targeting the isoprenoid pathway to control toxoplasma gondii infections - toxoplasma gondii is the responsible parasite for toxoplasmosis, one of the most prevalent parasitic…
Active Grant Awarded
- Award ID
- R01AI183432
- Recipient
-
Facultad De Ciencias Exactas Y Naturales De La Universidad De Buenos Aires UEI XJMCXTGNAK48
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $144,550
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 4% complete
- Place of performance
- Argentina
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Institute of Allergy and Infectious Diseases, awarded Facultad De Ciencias Exactas Y Naturales De La Universidad De Buenos Aires (Fcen-Uba) a grant of $144,550 on September 10, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The award funds research on linear bisphosphonates that target the isoprenoid pathway to control Toxoplasma gondii infection, the parasite that causes toxoplasmosis. The project centers on farnesyl diphosphate synthase as a drug target and on two compounds, 1-[(N-decylsulfonyl)ethyl]-1,1-bisphosphonate (CP-22) and 1-[(N-heptylthio)ethyl]-1,1-bisphosphonate (C7S). The project narrative reports that CP-22 protected mice against a lethal infection at 0.02 mg/kg/day for 10 days, and that C7S combined with atorvastatin showed a synergistic effect. Both compounds reduced brain tissue cysts in a chronic mouse model. The obligated amount is $144,550, the award is a grant, and the ultimate completion date is August 31, 2031. Place of performance is Argentina.
Description
Linear bisphosphonates targeting the isoprenoid pathway to control toxoplasma gondii infections - toxoplasma gondii is the responsible parasite for toxoplasmosis, one of the most prevalent parasitic diseases affecting close to one billion people worldwide. T. Gondii can infect a wide range of hosts, such as humans and warm-blooded animals. Toxoplasmosis is usually asymptomatic, whereas T. Gondii is a major opportunistic pathogen of immune-deficient patients after organ transplantation or cancer chemotherapy. Infection of the fetus during pregnancy can cause severe ocular disease. The current chemotherapy is still deficient and can produce toxic side effects, does not adequately reach the central nervous system, or is very expensive. Thus, there is a critical need to develop new safe drugs based on the knowledge of the biochemistry and physiology of T. Gondii. Farnesyl diphosphate synthase (FPPS) is a valid target for drug design against T. Gondii and catalyzes farnesyl and geranylgeranyl diphosphates formation. T. Gondii lacks the mevalonate pathway and uses the essential 1-deoxy-D-xylulose-5-phosphate (DOXP) pathway to make isopentenyl and dimethylallyl diphosphates. In addition, our laboratory have synthesized various highly effective bisphosphonates targeting tgfpps where 1-[(N- decylsulfonyl)ethyl]-1,1-bisphosphonate (CP-22) arises as a relevant compound. This sulfone- containing molecule is effective in protecting mice against a lethal T. Gondii infection (0.02 MG/KG/day for 10 days). This remarkable low dose is considerable better than the one with the established drug atovaquone. In addition, 1-[(N-HEPTYLTHIO)ethyl]-1,1-bisphosphonate (C7S) shows a highly synergistic effect against a lethal T. Gondii infection when combined with ATORVASTATIN [1.25 MG/KG/day (ATORVASTATIN) and 0.03 MG/KG/day (C7S) for 10 days]. Both CP-22 and C7S are effective at reducing the number of brain tissue cysts in the chronic mouse model. Our hypothesis is that bisphosphonates will be highly effective to control both acute and chronic toxoplasmosis. To test this hypothesis, our specific aims are: 1. Perform structure-activity relationship studies to assist drug design and synthesis of CP-22 derivatives with better distribution and permeability. Information from in vitro growth, toxicity, and pharmacokinetic results will be used for chemical improvement of the drugs. Most promising compounds will be tested in the acute and chronic models of T. Gondii infection. 2. Perform structure-activity relationship studies to assist drug design and synthesis of C7S derivatives. These drugs will also be tested for synergy with statins and other mitochondrial inhibitors. Our goal is to obtain an ideal drug or combination for the treatment of T. Gondii with improved cell permeability and low toxicity that could be also effective against other apicomplexan infections.
Quick answers
Who received award R01AI183432?
R01AI183432 was awarded to Facultad De Ciencias Exactas Y Naturales De La Universidad De Buenos Aires by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 10, 2026.
How much is award R01AI183432 worth?
$144,550 has been obligated on R01AI183432.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award